Critical Survey: Omeros Corporation (NASDAQ:OMER) versus The Competition

Omeros Corporation (NASDAQ: OMER) is one of 292 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Omeros Corporation to similar businesses based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares Omeros Corporation and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Omeros Corporation $53.60 million -$48.15 million -13.47
Omeros Corporation Competitors $258.58 million $65.85 million -7.26

Omeros Corporation’s peers have higher revenue and earnings than Omeros Corporation. Omeros Corporation is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

44.9% of Omeros Corporation shares are held by institutional investors. Comparatively, 50.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 12.1% of Omeros Corporation shares are held by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Omeros Corporation and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omeros Corporation 0 1 5 1 3.00
Omeros Corporation Competitors 741 2975 11076 223 2.72

Omeros Corporation presently has a consensus price target of $33.38, suggesting a potential upside of 69.76%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 31.80%. Given Omeros Corporation’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Omeros Corporation is more favorable than its peers.

Volatility and Risk

Omeros Corporation has a beta of 3.57, meaning that its stock price is 257% more volatile than the S&P 500. Comparatively, Omeros Corporation’s peers have a beta of 6.66, meaning that their average stock price is 566% more volatile than the S&P 500.

Profitability

This table compares Omeros Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Omeros Corporation -117.61% N/A -62.51%
Omeros Corporation Competitors -5,801.68% -451.23% -42.41%

Summary

Omeros Corporation peers beat Omeros Corporation on 7 of the 12 factors compared.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply